These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24702884)
1. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Yilmaz G; Akyol G; Cakir A; Ilhan M Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884 [TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115 [TBL] [Abstract][Full Text] [Related]
4. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791 [TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575 [TBL] [Abstract][Full Text] [Related]
6. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma. Jiang S; Pei L; Yang ZL; Liu G Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038 [TBL] [Abstract][Full Text] [Related]
8. The Expressions of CD44, CD90 and Alpha Fetoprotein Biomarkers in Indonesian Patients with Advanced Liver Disease: an Observational Study. Mustika S; Wijaya H; Pratomo B Acta Med Indones; 2019 Apr; 51(2):137-144. PubMed ID: 31383828 [TBL] [Abstract][Full Text] [Related]
9. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis. Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258 [TBL] [Abstract][Full Text] [Related]
10. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Jia Q; Zhang X; Deng T; Gao J Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193 [TBL] [Abstract][Full Text] [Related]
11. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346 [TBL] [Abstract][Full Text] [Related]
12. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma. Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842 [TBL] [Abstract][Full Text] [Related]
13. Surface markers of hepatocellular cancer stem cells and their clinical potential. Feng D; Wang N; Hu J; Li W Neoplasma; 2014; 61(5):505-13. PubMed ID: 24712843 [TBL] [Abstract][Full Text] [Related]
14. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Ma YC; Yang JY; Yan LN Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672 [TBL] [Abstract][Full Text] [Related]
15. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of stem cell marker CD133 expression in colorectal cancer. Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717 [TBL] [Abstract][Full Text] [Related]
17. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Chen WC; Chang YS; Hsu HP; Yen MC; Huang HL; Cho CY; Wang CY; Weng TY; Lai PT; Chen CS; Lin YJ; Lai MD Oncotarget; 2015 Dec; 6(40):42923-37. PubMed ID: 26556861 [TBL] [Abstract][Full Text] [Related]
18. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma. Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. Xi HQ; Zhao P J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]